Does Sunbed Radiation With Mainly UVA Provoke Cutaneous Vitamin D Synthesis in Humans?

August 15, 2007 updated by: Bispebjerg Hospital

Sunbed Radiation Provoke Cutaneous Vitamin D Synthesis in Humans, a Randomized Controlled Trial

We would investigate in a controlled, randomized open study in the winter season: 1) If serum levels of vitamin D (25(OH)D) increase in subjects treated with sunbed with sunlamps emitting mainly UVA and only 0·5% or 1·4% UVB compared to non-sunbed treated controls 2) If yes, are the 25(OH)D serum levels then dependent on the UVB dose?

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

41

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Copenhagen, Denmark, DK-2000 NV
        • Bispebjerg Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Healthy
  • Females
  • Above 50 years
  • Younger with serum concentration of 25(OH)D below 50nmol/l

Exclusion Criteria:

  • No sunbed use last ½ year
  • No sun holiday last ½ year
  • No intake of vitamin D above 10 microgram/day

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Controls
Active Comparator: UVB 0.5%
Radiation: UV radiation
UV radiation with 99.5% UVA and 0.5%UVB
Radiation: UV radiation
UVB 1.4 % and UVA 98.6
Active Comparator: UVB 1.4%
Radiation: UV radiation
UV radiation with 99.5% UVA and 0.5%UVB
Radiation: UV radiation
UVB 1.4 % and UVA 98.6

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Serum concentration of 25(OH)D
Time Frame: 18 Days
18 Days

Secondary Outcome Measures

Outcome Measure
Time Frame
Serum concentration of PTH
Time Frame: 18 Days
18 Days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bispebjerg Hospital

Collaborators

Hvidovre University Hospital

Investigators

  • Study Chair: Hans C Wulf, MD, DSc, Bispebjerg Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2006

Study Completion (Actual)

April 1, 2006

Study Registration Dates

First Submitted

August 14, 2007

First Submitted That Met QC Criteria

August 15, 2007

First Posted (Estimate)

August 16, 2007

Study Record Updates

Last Update Posted (Estimate)

August 16, 2007

Last Update Submitted That Met QC Criteria

August 15, 2007

Last Verified

August 1, 2007

More Information

Terms related to this study

Other Study ID Numbers

  • KF 01 290815

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on UV radiation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe